Lemalesomab

{{Short description|Monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 458270465

| image =

| type = mab

| mab_type = mab

| source = o

| target = NCA-90 (granulocyte antigen)

| tradename =

| pregnancy_category =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 250242-54-7

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 018649S21N

| ATC_prefix = none

| ATC_suffix =

| ATC_supplemental =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| chemical_formula =

| molecular_weight =

}}

Lemalesomab is a mouse monoclonal antibody for the diagnosis of inflammatory lesions.{{cite journal | title = International Nonproprietary Names (INN) for Pharmaceutical Substances Proposed INN: List 84 | url = http://whqlibdoc.who.int/druginfo/DRUG_INFO_14_4_2000_INN-84.pdf | journal = WHO Drug Information | volume = 14 | issue = 4 | date = 2000 | page = 260 }}{{cite book | vauthors = Pelletier JP | chapter = Chapter 16 - Passive Monoclonal and Polyclonal Antibody Therapies | veditors = Maitta RW | chapter-url = https://books.google.com/books?id=4PWrDwAAQBAJ&dq=Lemalesomab&pg=PA296 | page = 296 |title=Immunologic concepts in transfusion medicine |date=2020 |publisher=Elsevier |location=Philadelphia |isbn=978-0-323-67510-9 | doi = 10.1016/B978-0-323-67509-3.00016-0 | s2cid = 213508934 }}